These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 16888617)
1. The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma. Bensinger WI Leukemia; 2006 Oct; 20(10):1683-9. PubMed ID: 16888617 [TBL] [Abstract][Full Text] [Related]
2. The current status of hematopoietic stem cell transplantation for multiple myeloma. Bensinger WI Clin Adv Hematol Oncol; 2004 Jan; 2(1):46-52. PubMed ID: 16163159 [TBL] [Abstract][Full Text] [Related]
3. Recent developments in hematopoietic stem cell transplantation for multiple myeloma. Bensinger WI Int J Hematol; 2003 Apr; 77(3):232-8. PubMed ID: 12731665 [TBL] [Abstract][Full Text] [Related]
4. Is there still a role for allogeneic stem-cell transplantation in multiple myeloma? Bensinger WI Best Pract Res Clin Haematol; 2007 Dec; 20(4):783-95. PubMed ID: 18070719 [TBL] [Abstract][Full Text] [Related]
8. The role of hematopoietic stem cell transplantation in the treatment of multiple myeloma. Bensinger WI J Natl Compr Canc Netw; 2004 Jul; 2(4):371-8. PubMed ID: 19795599 [TBL] [Abstract][Full Text] [Related]
15. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma. Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737 [TBL] [Abstract][Full Text] [Related]
16. Allogeneic hematopoietic stem cell transplantation for multiple myeloma: curative but not the standard of care. Koehne G; Giralt S Curr Opin Oncol; 2012 Nov; 24(6):720-6. PubMed ID: 22960558 [TBL] [Abstract][Full Text] [Related]
17. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma. Gahrton G; Iacobelli S; Bandini G; Björkstrand B; Corradini P; Crawley C; Hegenbart U; Morgan G; Kröger N; Schattenberg A; Schönland SO; Verdonck LF; Volin L; de Witte T; Niederwieser D; Haematologica; 2007 Nov; 92(11):1513-8. PubMed ID: 18024400 [TBL] [Abstract][Full Text] [Related]
18. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma. Levenga H; Schaap N; Maas F; Esendam B; Fredrix H; Greupink-Draaisma A; de Witte T; Dolstra H; Raymakers R Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972 [TBL] [Abstract][Full Text] [Related]
19. The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy. Kyle RA Ann Oncol; 2000; 11 Suppl 1():55-8. PubMed ID: 10707780 [TBL] [Abstract][Full Text] [Related]